EN DE
STOCK COMPARISON

Carilex Medical vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Carilex Medical (7726) and Abbott Laboratories (ABT) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Carilex Medical as the less overvalued of the two: Carilex Medical trades at TWD 32.15 versus a fair value of TWD 22.35 (-30%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Carilex Medical
7726.TWO · TWD · Healthcare
-30%
upside to fair value
overvalued
PriceTWD 32.15
Fair ValueTWD 22.35
Quality40/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Carilex MedicalAbbott Laboratories
Valuation
P/E (TTM)27.7×
P/S (TTM)3.89×
0.07×P/B3.36×
EV/EBITDA15.1×
PEG1.47×
Profitability
0%Net margin14%
0%Operating margin13%
Return on equity12%
0%Return on assets6%
Growth
0%Revenue growth (YoY)8%
0.3%Avg. growth/yr (3Y)0.5%
-0.5%Avg. growth/yr (5Y)5.1%
Balance & size
Debt / equity0.19×
$20MMarket cap$175B
weakGrowth qualityhealthy

Abbott Laboratories leads: 1 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Carilex Medicalof which business quality 42 · market factors 43 Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
15
50
Quality GrowthAre margins and returns improving?
1
47
CashflowEarnings quality: real cash, not paper profit
59
71
Fin. StrengthBalance sheet, leverage, solvency risk
83
80
InvestmentDisciplined investing over empire-building
72
65
Low VolatilityCalm price path (market factor)
82
83
MomentumPrice trend over the last 3–12 months (market factor)
32
40
52W MomentumDistance to the 52-week high (market factor)
17
33
Net IssuanceBuybacks instead of dilution
11
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Carilex Medical

DCF ModelsTWD 29.83
MultiplesTWD 34.12
Asset-BasedTWD 9.60
Growth DCFTWD 31.32

4 of 7 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Carilex Medical
Bear TWD 16.46Fair Value TWD 22.35Bull TWD 28.23
TWD 32.15 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Carilex Medical · Healthcare

Quality score40 · below median
Fair value upside-30% · below median

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-31% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Carilex Medical as the less overvalued of the two: Carilex Medical trades at TWD 32.15 versus a fair value of TWD 22.35 (-30%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).

Abbott Laboratories has the higher quality score (67/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.